Technical Analysis for UROV - Urovant Sciences Ltd.

Grade Last Price % Change Price Change
grade B 10.5 -2.69% -0.29
UROV closed down 2.69 percent on Wednesday, February 20, 2019, on 2.33 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical UROV trend table...

Date Alert Name Type % Chg
Feb 20 Upper Bollinger Band Walk Strength 0.00%
Feb 20 Overbought Stochastic Strength 0.00%
Feb 20 Upper Bollinger Band Touch Strength 0.00%
Feb 19 180 Bullish Setup Bullish Swing Setup -2.69%
Feb 19 Slingshot Bullish Bullish Swing Setup -2.69%
Feb 19 Stochastic Reached Overbought Strength -2.69%
Feb 19 Upper Bollinger Band Walk Strength -2.69%
Feb 19 Multiple of Ten Bullish Other -2.69%
Feb 19 Above Upper BB Strength -2.69%
Feb 19 Overbought Stochastic Strength -2.69%

Older signals for UROV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Medicine Biopharmaceutical Medical Specialties Chemical Compounds Irritable Bowel Syndrome Urology Benign Prostatic Hyperplasia Overactive Bladder Hyperplasia Roivant Sciences
Is UROV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.32
52 Week Low 4.055
Average Volume 44,431
200-Day Moving Average 0.0
50-Day Moving Average 7.8058
20-Day Moving Average 9.2715
10-Day Moving Average 9.668
Average True Range 0.7308
ADX 43.55
+DI 32.3306
-DI 10.4236
Chandelier Exit (Long, 3 ATRs ) 8.7976
Chandelier Exit (Short, 3 ATRs ) 10.6324
Upper Bollinger Band 10.6055
Lower Bollinger Band 7.9375
Percent B (%b) 0.96
BandWidth 28.776358
MACD Line 0.6162
MACD Signal Line 0.5001
MACD Histogram 0.1161
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.24
Resistance 3 (R3) 11.30 11.12 11.11
Resistance 2 (R2) 11.12 10.93 11.09 11.07
Resistance 1 (R1) 10.81 10.82 10.72 10.75 11.03
Pivot Point 10.63 10.63 10.59 10.60 10.63
Support 1 (S1) 10.32 10.44 10.23 10.26 9.97
Support 2 (S2) 10.14 10.33 10.11 9.93
Support 3 (S3) 9.83 10.14 9.89
Support 4 (S4) 9.77